[go: up one dir, main page]

AU2001263443A1 - F-protein epitope-based vaccine for respiratory syncytial virus infection - Google Patents

F-protein epitope-based vaccine for respiratory syncytial virus infection

Info

Publication number
AU2001263443A1
AU2001263443A1 AU2001263443A AU6344301A AU2001263443A1 AU 2001263443 A1 AU2001263443 A1 AU 2001263443A1 AU 2001263443 A AU2001263443 A AU 2001263443A AU 6344301 A AU6344301 A AU 6344301A AU 2001263443 A1 AU2001263443 A1 AU 2001263443A1
Authority
AU
Australia
Prior art keywords
virus infection
respiratory syncytial
syncytial virus
based vaccine
protein epitope
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001263443A
Inventor
Mark S. Hanson
Scott Koenig
Joann Suzich
Nancy Ulbrandt
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
MedImmune LLC
Original Assignee
MedImmune LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by MedImmune LLC filed Critical MedImmune LLC
Publication of AU2001263443A1 publication Critical patent/AU2001263443A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/12Viral antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/12Viral antigens
    • A61K39/155Paramyxoviridae, e.g. parainfluenza virus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/60Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031Proteins
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011Details
    • C12N2760/18011Paramyxoviridae
    • C12N2760/18511Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18522New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011Details
    • C12N2760/18011Paramyxoviridae
    • C12N2760/18511Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18534Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pulmonology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AU2001263443A 2000-05-25 2001-05-25 F-protein epitope-based vaccine for respiratory syncytial virus infection Abandoned AU2001263443A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US20694600P 2000-05-25 2000-05-25
US60206946 2000-05-25
PCT/US2001/017022 WO2001089562A1 (en) 2000-05-25 2001-05-25 F-protein epitope-based vaccine for respiratory syncytial virus infection

Publications (1)

Publication Number Publication Date
AU2001263443A1 true AU2001263443A1 (en) 2001-12-03

Family

ID=22768618

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001263443A Abandoned AU2001263443A1 (en) 2000-05-25 2001-05-25 F-protein epitope-based vaccine for respiratory syncytial virus infection

Country Status (3)

Country Link
US (1) US20020018780A1 (en)
AU (1) AU2001263443A1 (en)
WO (1) WO2001089562A1 (en)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001064751A2 (en) * 2000-03-01 2001-09-07 Medimmune, Inc. High potency recombinant antibodies and method for producing them
PT1265928E (en) * 2000-01-27 2010-09-30 Medimmune Llc NEUTRALIZING ANTIBODIES WITH ULTRA-HIGH AFFINITY
US7179900B2 (en) * 2000-11-28 2007-02-20 Medimmune, Inc. Methods of administering/dosing anti-RSV antibodies for prophylaxis and treatment
US6855493B2 (en) * 2000-11-28 2005-02-15 Medimmune, Inc. Methods of administering/dosing anti-RSV antibodies for prophylaxis and treatment
US7425618B2 (en) * 2002-06-14 2008-09-16 Medimmune, Inc. Stabilized anti-respiratory syncytial virus (RSV) antibody formulations
US7132100B2 (en) 2002-06-14 2006-11-07 Medimmune, Inc. Stabilized liquid anti-RSV antibody formulations
TW200501985A (en) * 2002-07-25 2005-01-16 Medimmune Inc Methods of treating and preventing RSV, hMPV, and PIV using anti-RSV, anti-hMPV, and anti-PIV antibodies
WO2006034292A2 (en) 2004-09-21 2006-03-30 Medimmune, Inc. Antibodies against and methods for producing vaccines for respiratory syncytial virus
AU2012202860B2 (en) * 2004-09-21 2015-04-02 Medlmmune, Llc Antibodies against and methods for producing vaccines for respiratory syncytial virus
US20060115485A1 (en) * 2004-10-29 2006-06-01 Medimmune, Inc. Methods of preventing and treating RSV infections and related conditions
WO2008045252A2 (en) * 2006-10-04 2008-04-17 The Board Of Trustees Of The Leland Stanford Junior University Engineered integrin binding peptides
EP1997830A1 (en) * 2007-06-01 2008-12-03 AIMM Therapeutics B.V. RSV specific binding molecules and means for producing them
WO2010087927A2 (en) 2009-02-02 2010-08-05 Medimmune, Llc Antibodies against and methods for producing vaccines for respiratory syncytial virus
US8568726B2 (en) 2009-10-06 2013-10-29 Medimmune Limited RSV specific binding molecule
US8778888B2 (en) * 2009-11-06 2014-07-15 The Board Of Trustees Of The Leland Stanford Junior University Cystine knot peptides binding to alpha IIb beta 3 integrins and methods of use
SMT202000145T1 (en) * 2013-02-01 2020-05-08 Medimmune Llc Respiratory syncytial virus f protein epitopes
WO2014152534A1 (en) 2013-03-14 2014-09-25 Emory University Recombinant rsv with silent mutations, vaccines, and methods related thereto
SG11201507978XA (en) * 2013-04-08 2015-10-29 Medimmune Llc Vaccine composition and method of use
SG11201803581VA (en) 2015-10-29 2018-05-30 Univ Emory Chimeric RSV, Immunogenic Compositions, and Methods of Use
US10350266B2 (en) 2017-01-10 2019-07-16 Nodus Therapeutics, Inc. Method of treating cancer with a multiple integrin binding Fc fusion protein
WO2018132516A1 (en) 2017-01-10 2018-07-19 Nodus Therapeutics Combination tumor treatment with an integrin-binding-fc fusion protein and immune modulator
US11680085B2 (en) * 2017-06-14 2023-06-20 Virometix Ag Cyclic peptides for protection against respiratory syncytial virus

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5639853A (en) * 1987-09-29 1997-06-17 Praxis Biologics, Inc. Respiratory syncytial virus vaccines
GB9207479D0 (en) * 1992-04-06 1992-05-20 Scotgen Ltd Novel antibodies for treatment and prevention of respiratory syncytial virus infection in animals and man

Also Published As

Publication number Publication date
WO2001089562A1 (en) 2001-11-29
US20020018780A1 (en) 2002-02-14

Similar Documents

Publication Publication Date Title
AU2001263443A1 (en) F-protein epitope-based vaccine for respiratory syncytial virus infection
EG24026A (en) Respiratory syncytial virus replication inhibitors
AU2002353378A1 (en) Vaccine for periodontal disease
HUP0201869A3 (en) Respiratory syncytial virus replication inhibitors
AU2001240109A1 (en) Dna vaccines against poxviruses
HUP0201789A3 (en) Respiratory syncytial virus replication inhibitors
AU2002229390A1 (en) Attenuated live vaccine
DE60038877D1 (en) COMBINATION VACCINE AGAINST STREPTOKKKUS PNEUMONIAE AND RESPIRATORY SYNCYTIAL VIRUS (RSV)
AU2002242935A1 (en) A process for the preparation of a non-toxic anthrax vaccine
AU2001238401A1 (en) Cold-adapted equine influenza viruses
AU2002322059A1 (en) Improved vaccination against anthrax
AU2001278337A1 (en) Respiratory syncytial virus vaccine
AU2001269640A1 (en) Vaccine against the influenza virus and method for producing said virus vaccine
AU2002230609A1 (en) Aerodynamically light vaccine for active pulmonary immunization
AU6964001A (en) Vaccine against the influenza virus and method for producing said virus vaccine
AU5918100A (en) Production of attenuated respiratory syncytial virus vaccines involving modification of M2 ORF2
AU2001278323A1 (en) Modified sialic acid vaccines
AU4606000A (en) Vaccine for newcastle disease virus
AU2002327959A1 (en) Adjuvants for nucleic acid vaccines
AU4957800A (en) Vaccine against isa virus
AU4994800A (en) Plant-derived antigens against respiratory syncytial virus
AU2002223398A1 (en) A vaccine for influenza virus and its preparation
AU2001271909A1 (en) Attenuated human-bovine chimeric parainfluenza virus (piv) vaccines
GB0114107D0 (en) Respiratory syncytial virus
AU2001291202A1 (en) Avian pneumovirus vaccine